CSF Aβ42 predicts early-onset dementia in Parkinson disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To test in vivo the proposal from clinicopathologic studies that β-amyloid (Aβ) pathology shortens the time to dementia in Parkinson disease (PD), and to explore the utility of CSF Aβ and related measures as early prognostic biomarkers of dementia in an incident PD cohort.
Methods: We assessed a population-based incident cohort of 104 patients with PD who underwent lumbar puncture at diagnosis. We analyzed CSF concentrations of Aβ42, Aβ40, and Aβ38 using a multiplexed immunoassay with electrochemiluminescence (ECL) detection and levels of Aβ42, total tau, and phosphorylated tau using ELISA. Patients were followed prospectively for 5 years. Dementia was diagnosed according to published criteria.
Results: CSF levels of Aβ42 were significantly decreased in patients who developed dementia (n = 20, 19.2%) compared to those who did not (n = 84, 80.8%), as measured by ECL (−33%, p = 0.006) as well as ELISA (−36%, p < 0.001). No differences were observed for other markers. Low Aβ42 values predicted a substantially increased risk for subsequent dementia at high sensitivity (≥85%), with hazard ratios of 9.9 (95% confidence interval 2.3–43.5, p = 0.002) for Aβ42ECL <376 pg/mL and 7.6 (2.2–26.4, p = 0.001) for Aβ42ELISA <443 pg/mL, after adjustment for baseline age and PD–mild cognitive impairment (MCI) status. Aβ42 reductions tended to precede the onset of PD-MCI that progressed to dementia.
Conclusions: These in vivo data support the role of Aβ pathology in the etiology and highlight the potential utility of CSF Aβ42 as an early prognostic biomarker of dementia associated with PD.
GLOSSARY
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- AUC=
- area under the receiver operating characteristic curve;
- CI=
- confidence interval;
- ECL=
- electrochemiluminescence;
- LP=
- lumbar puncture;
- MCI=
- mild cognitive impairment;
- MMSE=
- Mini-Mental State Examination;
- NPV=
- negative predictive value;
- PD=
- Parkinson disease;
- PDD=
- Parkinson disease dementia;
- PPV=
- positive predictive value;
- ROC=
- receiver operating characteristic
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 1758
Supplemental data at Neurology.org
- Received June 27, 2013.
- Accepted in final form January 16, 2014.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
REM behavior disorder predicts motor progression and cognitive decline in Parkinson diseaseGennaro Pagano, Rosa De Micco, Tayyabah Yousaf et al.Neurology, August 08, 2018 -
Articles
Cognitive impairment in incident, untreated Parkinson diseaseThe Norwegian ParkWest StudyD. Aarsland, K. Brønnick, J. P. Larsen et al.Neurology, November 19, 2008 -
Article
CSF biomarkers in Olmsted CountyEvidence of 2 subclasses and associations with demographicsArgonde C. Van Harten, Heather J. Wiste, Stephen D. Weigand et al.Neurology, June 26, 2020 -
Articles
CSF amyloid β 1-42 predicts cognitive decline in Parkinson diseaseA. Siderowf, S.X. Xie, H. Hurtig et al.Neurology, August 18, 2010